

**CML Biological and Clinical Investigator Meeting on  
Intermittent and Discontinued Treatment with TKIs  
19-Settembre-2016**

**Aula E  
Facoltà di Medicina e Chirurgia  
Università di Brescia  
Viale Europa 11- Brescia**

10.20 - 10.30 Welcome and Introduction (D. Russo)

**I Session – Focus on intermittent and discontinued TKIs Therapy in CML**

*Chairman: G. Specchia - D.Russo*

10.30 - 10.45 Clinical rationale and perspectives of intermittent and discontinued TKIs treatment in CML (M. Baccarani)

10.45 - 11.00 Biological end-points and MRD monitoring in the case of intermittent and discontinued TKIs treatment in CML (G. Saglio)

11.00 - 11.15 Why the Quality of Life became a major goal of CML therapy ( F. Efficace)

11.15 - 11.30 Discussion

*Chairman: F. Pane - G. Martinelli*

11.30 - 12.30 New methods for biological characterization, prognosis and monitoring of CML

- *The dPCR: preliminary results (S. Bernardi)*

- *The dPCR standardization (E. Gottardi)*

- *The NGS (S. Soverini)*

12.30 - 13.00 Discussion

*13.00 - 14.00 Light - Lunch*

**II Session – Update and Discussion on intermittent and discontinued TKIs CML Trials**

*Chairman: G. Rossi - M. Tiribelli*

14.00 - 14.10 Update on INTERIM 0407 study (N. Polverelli)

14.10 - 14.20 Update on OPTKIMA 1013 study (M. Malagola)

14.20 - 14.30 OPTIMA Top Leader Center : Single Experience ( A. Iurlo)

14.30 - 14.45 Update on SUSTRENIM 1415 study (F. Pane)

- 14.45 - 15.00 Update on AID MORE (F. Di Raimondo)
- 15.00-15.15 New Proposal ( C. Fava)
- 15.15 - 16.00 General Discussion  
(M. Baccarani, G. Saglio, F. Pane, G. Martinelli, G. Specchia, F. Di Raimondo, G. Rossi,  
M. Tiribelli, D.Russo)
- 16.00-16.30 Closing remarks (D. Russo)